LIOCYXM-004 is under clinical development by Lion TCR and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LIOCYXM-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LIOCYXM-004 overview
LioCyxM-004 is under development for the treatment of Hepatitis B Virus (HBV)-related hepatocellular carcinoma and hepatocellular carcinoma recurrence in post liver resection and transplantation. It is administered through intravenous route. The therapeutic candidate comprises of autologous T cells transfected with mRNA encoding HBV antigen-specific TCR. The drug candidate is developed based on T-cell receptor (TCR) therapy platform.
Lion TCR overview
Lion TCR., is a clinical-stage biotechnology company that develops cell therapy for cancers and life-threatening infectious diseases. The company is headquartered in Singapore.
For a complete picture of LIOCYXM-004’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
